The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. DS3790 is a specifically engineered, ...
At a recent roundtable in Chennai hosted as a part of AI@Work series organised byThe Hindu Group in association with IBM, ...
If you have a target retirement age circled on your calendar, you might be planning around the wrong metric. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results